Roche Pharma Chief Picks Out Pearls in Cancer Pipeline
Big Plans For TIGIT And SERD Drugs
Oncology is an area where the Swiss major has long been a dominant player, and Bill Anderson highlighted programs to Scrip which Roche hopes will help extend that dominance.
